Diabetes Dialogue: Key Updates in ADA Standards of Care—2024

News
Article

Hosts discuss what they consider the most significant or relevant updates in the ADA's Standards of Care—2024, with a focus on new recommendations for glycemic management, bone health, immunizations, and weight management.

Each year, the American Diabetes Association (ADA) Standards of Care serve as a roadmap for clinicians and diabetes educators to understand and apply the latest updates in the management of diabetes. Unlike guidelines and recommendation statements from other major professional medical organizations, the ADA Standards of Care have undergone annual updates capturing the latest developments in diabetes management dating back to 1989.

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss what they consider the most significant or relevant updates in the ADA’s Standards of Care in Diabetes—2024.

During the episode, hosts detail the importance of the document’s patient-first language as well as provide their reactions and perspectives on updates to the following sections of the document:

  • Section 4. Comprehensive Medical Evaluation and Assessment of Comorbidities
  • Section 6. Glycemic Goals and Hypoglycemia
  • Section 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes

Of note, when discussing updates in section 4, hosts make specific mention of new recommendations related to bone health and immunizations. In a previous episode, hosts provided insight into updates of note from the section of the ADA’s Standards of Care in Diabetes—2024 related to use of and access to diabetes technology.

Relevant disclosures for Dr. Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

References:

  1. American Diabetes Association Professional Practice Committee . Summary of Revisions: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Supplement_1):S5-S10. doi:10.2337/dc24-SREV
Related Videos
Wei Zhang, MD, PhD | Credit: Mass General Brigham
Robert Wood, MD | Credit: LinkedIn
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Tom Nguyen, MD | Credit: Baptist Health
Marla Dubinsky, MD | Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.